Wockhardt raises Rs 480 crore to pare debt, fund drug trial

Wockhardt plans to clear debt, fund antibiotic trials with QIP funds. Khorakiwala expects revenue growth, EBITDA rise, and completion of global antibiotic trial for innovations like WCK5222 and WCK4873.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Ti4XZfI
via IFTTT

0 comments:

Post a Comment